Ziccum SEK 30m Capital Raise | Q4 2024

About Ziccum 

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes.The technology has successfully been applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application.

The case 

• Ziccum has developed a unique technology, LaminarPace™, which will be integrated into the commercial supply chain of biological pharmaceutical products, with a current focus on vaccines and mRNA-based products.
• Ziccum has confirmed that the inhalable particles of mRNA/LNP materials generated by LaminarPace™ have a perfect, ideal morphology for delivery by inhalation.
• Inhalable mRNA/LNP entails increased storage stability compared to liquid formulations, simplified and preferred patient administration avoiding injections.
• Inhalable mRNA/LNP therapies do not exist on the market today, as the elevated temperatures of conventional drying methods are not applicable for the highly delicate mRNA/LNP materials. Ziccum’s LaminarPace™ technology is applied at room temperature with minimal stress factors, enabling a very gentle treatment compared to other methods.
• Current revenues are generated by paid evaluation studies and milestone payments. Commercial-stage revenues will be generated through royalty payments based on drug and vaccine sales by licensees.
• Ziccum implemented a new strategy and business model in 2022, which resulted in a broad pipeline of client dialogues, with revenue generation from paid evaluation studies. Recent key milestones with significant proof for the mRNA/LNP platform were reached in 2023 and 2024. 

Website: https://ziccum.com/